Mipomersen (Kynamro) Approved by FDA

On January 29, the U.S. FDA approved mipomersen sodium injection as an adjunct to treat LDL-C, Apo B, total cholesterol, and non HDL-C in patients with homozygous familial hypercholesterolemia (HoFH). Mipomersen, known by the brand name Kynamro, will be marketed in the U.S. by Genzyme, a Sanofi company. The mipomersen clearance follows a 9-6 vote in favor of the drug's approval by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee this past October.